<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39371770</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Diagnosis of COVID-19: Is Fever the Best Indicator of COVID-19 in Vaccinated SARS-CoV-2-Positive Adults?</ArticleTitle><Pagination><StartPage>e68749</StartPage><MedlinePgn>e68749</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e68749</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.68749</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Coronavirus disease 2019 (COVID-19) vaccination is highly recommended to prevent the onset and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Japan. However, the impact of COVID-19 vaccination on the manifestations or presenting symptoms of SARS-CoV-2 infection in daily clinical practice remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective single-center study was conducted from April 2021 to July 2022 in Japan. We compared the clinical manifestations of SARS-CoV-2 infection in 636 COVID-19-positive patients who visited our outpatient fever clinic, both COVID-19-vaccinated and unvaccinated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During the study period, the COVID-19 vaccination rate at the time of infection was 77.2% (n=491/636), with a median of two doses. Most manifestations, including fever, were reduced in the vaccinated group (n=196) compared to the non-vaccinated group (n=142). The temperature at the clinic decreased significantly as the number of vaccinations increased. Fever was the most common manifestation in the non-vaccinated group (76%, n=108/142), while only 30% (n=59/196) of those who received three or more COVID-19 vaccinations experienced fever. However, sore throat and cough were observed more frequently in the vaccinated group compared to the non-vaccinated group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Fever may not be a reliable indicator of SARS-CoV-2 infection in vaccinated individuals, as its frequency is significantly reduced by vaccination. However, since sore throat and cough are more frequently observed in vaccinated individuals, these symptoms could be useful for recommending COVID-19 testing even in the absence of fever, aiding in the prevention of infectious outbreaks.</AbstractText><CopyrightInformation>Copyright © 2024, Inaba et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inaba</LastName><ForeName>Shinji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, Pulmonology, and Cardiology, Ehime University Graduate School of Medicine, Toon, JPN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Imabari City Medical Association General Hospital, Imabari, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Shuntaro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Pulmonology, Hypertension, and Nephrology, Ehime University Graduate School of Medicine, Toon, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujiwara</LastName><ForeName>Yuta</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, Imabari City Medical Association General Hospital, Imabari, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sogabe</LastName><ForeName>Kyosei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, Imabari City Medical Association General Hospital, Imabari, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Katusji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Pulmonology, Hypertension, and Nephrology, Ehime University Graduate School of Medicine, Toon, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nogami</LastName><ForeName>Naoyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, Pulmonology, and Cardiology, Ehime University Graduate School of Medicine, Toon, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Eiichi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Imabari City Medical Association General Hospital, Imabari, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Pulmonology, Hypertension, and Nephrology, Ehime University Graduate School of Medicine, Toon, JPN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">fever</Keyword><Keyword MajorTopicYN="N">public health</Keyword><Keyword MajorTopicYN="N">symptoms</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>Human subjects: Consent was obtained or waived by all participants in this study. Ehime University Graduate School of Medicine issued approval #2201006. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39371770</ArticleId><ArticleId IdType="pmc">PMC11455972</ArticleId><ArticleId IdType="doi">10.7759/cureus.68749</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>COVID-19 and excess all-cause mortality in the US and 20 comparison countries, June 2021-March 2022. Bilinski A, Thompson K, Emanuel E. JAMA. 2023;329:92–94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9856868</ArticleId><ArticleId IdType="pubmed">36399335</ArticleId></ArticleIdList></Reference><Reference><Citation>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. Baden LR, El Sahly HM, Essink B, et al. N Engl J Med. 2021;384:403–416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. Polack FP, Thomas SJ, Kitchin N, et al. N Engl J Med. 2020;383:2603–2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 vaccination and estimated public health impact in California. Tan ST, Park HJ, Rodríguez-Barraquer I, Rutherford GW, Bibbins-Domingo K, Schechter R, Lo NC. JAMA Netw Open. 2022;5:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034409</ArticleId><ArticleId IdType="pubmed">35452106</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Kanda Y. Bone Marrow Transplant. 2013;48:452–458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3590441</ArticleId><ArticleId IdType="pubmed">23208313</ArticleId></ArticleIdList></Reference><Reference><Citation>Simple symptom-based prediction of COVID-19: a single-center study of outpatient fever clinic in Japan. Inaba S, Nakao Y, Ikeda S, et al. Cureus. 2023;15:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10122750</ArticleId><ArticleId IdType="pubmed">37155444</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 symptoms at time of testing and association with positivity among outpatients tested for SARS-CoV-2. Wohl DA, Barzin AH, Napravnik S, et al. PLoS One. 2021;16:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8664207</ArticleId><ArticleId IdType="pubmed">34890441</ArticleId></ArticleIdList></Reference><Reference><Citation>Development and validation of a clinical symptom-based scoring system for diagnostic evaluation of COVID-19 patients presenting to outpatient department in a pandemic situation. Bhattacharya A, Ranjan P, Kumar A, et al. Cureus. 2021;13:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8018900</ArticleId><ArticleId IdType="pubmed">33833907</ArticleId></ArticleIdList></Reference><Reference><Citation>A symptom-based rule for diagnosis of COVID-19. Smith DS, Richey EA, Brunetto WL. SN Compr Clin Med. 2020;2:1947–1954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7584484</ArticleId><ArticleId IdType="pubmed">33134843</ArticleId></ArticleIdList></Reference><Reference><Citation>Predictors of COVID-19 in an outpatient fever clinic. Trübner F, Steigert L, Echterdiek F, et al. PLoS One. 2021;16:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8294531</ArticleId><ArticleId IdType="pubmed">34288955</ArticleId></ArticleIdList></Reference><Reference><Citation>Association of mRNA vaccination with clinical and virologic features of COVID-19 among us essential and frontline workers. Thompson MG, Yoon SK, Naleway AL, et al. JAMA. 2022;328:1523–1533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9579910</ArticleId><ArticleId IdType="pubmed">36255426</ArticleId></ArticleIdList></Reference><Reference><Citation>Household transmission of SARS-CoV-2: a systematic review and meta-analysis. Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. JAMA Netw Open. 2020;3:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737089</ArticleId><ArticleId IdType="pubmed">33315116</ArticleId></ArticleIdList></Reference><Reference><Citation>Modelling of a triage scoring tool for SARS-COV-2 PCR testing in health-care workers: data from the first German COVID-19 testing unit in Munich. Hohl HT, Froeschl G, Hoelscher M, Heumann C. BMC Infect Dis. 2022;22:664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9341161</ArticleId><ArticleId IdType="pubmed">35915394</ArticleId></ArticleIdList></Reference><Reference><Citation>Prospects for a safe COVID-19 vaccine. Haynes BF, Corey L, Fernandes P, et al. Sci Transl Med. 2020;12</Citation><ArticleIdList><ArticleId IdType="pubmed">33077678</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. DiPiazza AT, Leist SR, Abiona OM, et al. Immunity. 2021;54:1869–1882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8249710</ArticleId><ArticleId IdType="pubmed">34270939</ArticleId></ArticleIdList></Reference><Reference><Citation>Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management. Ikewaki N, Kurosawa G, Levy GA, Preethy S, Abraham SJ. Vaccine. 2023;41:2427–2429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9992059</ArticleId><ArticleId IdType="pubmed">36906407</ArticleId></ArticleIdList></Reference><Reference><Citation>IgG4 antibodies induced by repeated vaccination may generate immune tolerance to the SARS-CoV-2 spike protein. Uversky VN, Redwan EM, Makis W, Rubio-Casillas A. Vaccines (Basel) 2023;11:991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10222767</ArticleId><ArticleId IdType="pubmed">37243095</ArticleId></ArticleIdList></Reference><Reference><Citation>Comparison of coronavirus disease 2019 (COVID-19) symptoms at diagnosis among healthcare personnel before and after the emergence of the omicron variant. Laracy JC, Robilotti EV, Yan J, Lucca A, Aslam A, Babady NE, Kamboj M. Infect Control Hosp Epidemiol. 2023;44:821–823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9068496</ArticleId><ArticleId IdType="pubmed">35506167</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>